108 related articles for article (PubMed ID: 19617903)
1. Pancreatic atrophy is associated with gastrointestinal chronic GVHD following allogeneic PBSC transplantation.
Nakasone H; Ito A; Endo H; Kida M; Koji I; Usuki K
Bone Marrow Transplant; 2010 Mar; 45(3):590-2. PubMed ID: 19617903
[No Abstract] [Full Text] [Related]
2. Pancreatic atrophy after allogeneic peripheral blood stem cell transplantation.
Moenen FC; Bakers FC; Bos GM
Br J Haematol; 2016 Jan; 172(2):155. PubMed ID: 26303722
[No Abstract] [Full Text] [Related]
3. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
[TBL] [Abstract][Full Text] [Related]
4. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
Mengarelli A; Iori AP; Romano A; Cerretti R; Cerilli L; De Propris MS; Fenu S; Moleti ML; De Felice L; Girelli G; Arcese W
Haematologica; 2003 Mar; 88(3):315-23. PubMed ID: 12651271
[TBL] [Abstract][Full Text] [Related]
5. To freeze or not to freeze peripheral blood stem cells prior to allogeneic transplantation from matched related donors.
Parody R; Caballero D; Márquez-Malaver FJ; Vázquez L; Saldaña R; Madrigal MD; Calderón C; Carrillo E; Lopez-Corral L; Espigado I; Carmona M; López-Villar O; Pérez-Simón JA
Eur J Haematol; 2013 Nov; 91(5):448-55. PubMed ID: 23710624
[TBL] [Abstract][Full Text] [Related]
6. Computed tomography findings in a patient with severe graft-versus-host disease of the gut.
Tan DC; Koh LP; Tan PH
Br J Haematol; 2007 Mar; 136(6):768. PubMed ID: 17129228
[No Abstract] [Full Text] [Related]
7. Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease.
Im JS; Abraham SC; Saliba RM; Rondon G; Ross WA; Rashid A; Shpall EJ; Popat U; Qazilbash MH; Hosing C; Oran B; Shah N; Tewari P; Nieto Y; Kebriaei P; Champlin RE; Alousi AM
Am J Surg Pathol; 2017 Nov; 41(11):1483-1490. PubMed ID: 28834808
[TBL] [Abstract][Full Text] [Related]
8. Lichenoid cutaneous chronic GvHD following Blaschko lines.
Vassallo C; Derlino F; Ripamonti F; Borroni G
Int J Dermatol; 2014 Apr; 53(4):473-5. PubMed ID: 24320596
[No Abstract] [Full Text] [Related]
9. Intensification of GVHD prophylaxis with low-dose ATG-F before allogeneic PBSC transplantation from HLA-identical siblings in adult patients with hematological malignancies: results from a retrospective analysis.
Bonifazi F; Bandini G; Arpinati M; Tolomelli G; Stanzani M; Motta MR; Rizzi S; Giudice V; Dan E; Massari E; Tazzari P; Bontadini A; Pagliaro P; Baccarani M
Bone Marrow Transplant; 2012 Aug; 47(8):1105-11. PubMed ID: 22101198
[TBL] [Abstract][Full Text] [Related]
10. Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study.
Al-Homsi AS; Cole K; Bogema M; Duffner U; Williams S; Mageed A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1315-20. PubMed ID: 25765556
[TBL] [Abstract][Full Text] [Related]
11. Survival and graft-versus-host disease in patients receiving peripheral stem cell compared to bone marrow transplantation from HLA-matched related donor: retrospective analysis of 334 consecutive patients.
Campregher PV; Hamerschlak N; Colturato VA; Mauad MA; de Souza MP; Bouzas LF; Tavares Rde C; Barros JC; Chiattone R; Paz A; Silla L; Vigorito AC; Miranda E; Funke VA; Flowers ME
Eur J Haematol; 2015 Nov; 95(5):421-5. PubMed ID: 25645430
[TBL] [Abstract][Full Text] [Related]
12. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.
Dhédin N; Chamakhi I; Perreault C; Roy DC; Sauvageau G; Ducruet T; Busque L; Fish D; Bélanger R; Roy J
Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397
[TBL] [Abstract][Full Text] [Related]
13. Outcome of allogeneic peripheral blood stem cell transplantation using matched sibling donors in patients with high-risk hematological diseases.
Sohn SK; Kim DH; Kim JG; Sung WJ; Baek JH; Lee NY; Won DI; Suh JS; Lee KS; Lee KB
Eur J Haematol; 2004 Jun; 72(6):430-6. PubMed ID: 15128422
[TBL] [Abstract][Full Text] [Related]
14. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
[TBL] [Abstract][Full Text] [Related]
15. Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCT.
Scholl S; Mügge LO; Issa MC; Kasper C; Pachmann K; Höffken K; Sayer HG
Bone Marrow Transplant; 2005 Jan; 35(2):183-90. PubMed ID: 15531897
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic atrophy in patients with chronic graft-versus-host disease.
Brook OR; Mullan CP; Mendiratta-Lala M; Joyce R; Sheiman R; Brook A; Siewert B
Abdom Imaging; 2014 Apr; 39(2):342-7. PubMed ID: 24441578
[TBL] [Abstract][Full Text] [Related]
17. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
18. Transplantation outcome in allogeneic PBSCT patients according to a new chronic GVHD grading system, including extensive skin involvement, thrombocytopenia, and progressive-type onset.
Sohn SK; Kim DH; Kim JG; Lee NY; Suh JS; Lee KS; Lee KB
Bone Marrow Transplant; 2004 Jul; 34(1):63-8. PubMed ID: 15133486
[TBL] [Abstract][Full Text] [Related]
19. Impact of stem cell source on allogeneic stem cell transplantation outcome in hematological malignancies.
Stamatović D; Balint B; Tukić L; Elez M; Tarabar O; Todorović M; Ostojić G; Tatomirovic Z; Ljubenov M; Marjanović S; Malesević M
Vojnosanit Pregl; 2011 Dec; 68(12):1026-32. PubMed ID: 22352263
[TBL] [Abstract][Full Text] [Related]
20. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
